Skip to main content
SpringerLink
Log in

The Hepatitis B Virus and Antiviral Drug Resistance: Causes, Patterns, and Mechanisms

  • Chapter
Antimicrobial Drug Resistance

Part of the book series: Infectious Disease ((ID))

This chapter will briefl y review the major aspects of the molecular virology and replication of HBV, and summarize the major viral mutants of clinical signifi cance that are associated with drug resistance. Also, the factors and mechanisms of drug resistance in hepatitis B will be discussed. Finally, strategies to prevent the emergence of drug resistance will be addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Chisari, F.V. and C. Ferrari, Hepatitis B virus immunopathogen-esis. Annu Rev Immunol 1995; 13: 29–60

    Article  PubMed  CAS  Google Scholar 

  2. Chen, B.F., et al., High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130(4): 1153–1168

    Article  PubMed  CAS  Google Scholar 

  3. Chen, C.H., et al., Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBVe antigen expression in Taiwan. J Clin Microbiol 2005; 43(12): 6000–6006

    Article  PubMed  CAS  Google Scholar 

  4. Kao, J.H., et al., Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124(2): 327–334

    Article  PubMed  CAS  Google Scholar 

  5. Lin, C.L., et al., Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int 2005; 25(3): 564–570

    Article  PubMed  Google Scholar 

  6. Song, B.C., et al., Comparison of full length sequences of hepatitis B virus isolates in hepatocellular carcinoma patients and asymptomatic carriers of Korea. J Med Virol 2005; 75(1): 13–19

    Article  PubMed  CAS  Google Scholar 

  7. Yotsuyanagi, H., et al., Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J Hepatol 2002; 37(3): 355–363

    Article  PubMed  CAS  Google Scholar 

  8. Bartholomeusz, A. and S.A. Locarnini, Antiviral drug resistance: clinical consequences and molecular aspects. Semin Liver Dis 2006; 26(2): 162–170

    Article  PubMed  CAS  Google Scholar 

  9. Locarnini, S., Molecular virology and the development of resistant mutants: implications for therapy. Semin Liver Dis 2005; 25(Suppl 1): 9–19

    Article  PubMed  CAS  Google Scholar 

  10. De Meyer, S., et al., Organ and species specificity of hepatitis B virus (HBV) infection: a review of literature with a special reference to preferential attachment of HBV to human hepatocytes. J Viral Hepat 1997; 4(3): 145–153

    Article  PubMed  Google Scholar 

  11. Rabe, B., et al., Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A 2003; 100(17): 9849–9854

    Article  PubMed  CAS  Google Scholar 

  12. Locarnini, S. and C. Birch, Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J Hepatol 1999; 30(3): 536–550

    Article  PubMed  CAS  Google Scholar 

  13. Bock, C.T., et al., Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994; 8(3): 215–229

    Article  PubMed  CAS  Google Scholar 

  14. Newbold, J.E., et al., The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995; 69(6): 3350–3357

    PubMed  CAS  Google Scholar 

  15. Ganem, D. and R. Schneider, Hepadnaviridae: the viruses and their replication. In Fields Virology, D.M. Knipe and P.M. Howley, Eds. 2001, Lippincott-Raven: Philadelphia. pp. 2923–2970

    Google Scholar 

  16. Bouchard, M.J. and R.J. Schneider, The enigmatic X gene of hepatitis B virus. J Virol 2004; 78(23): 12725–12734

    Article  PubMed  CAS  Google Scholar 

  17. Bartenschlager, R. and H. Schaller, Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J 1992; 11(9): 3413–3420

    PubMed  CAS  Google Scholar 

  18. Will, H., et al., Replication strategy of human hepatitis B virus. J Virol 1987; 61(3): 904–911

    PubMed  CAS  Google Scholar 

  19. Zoulim, F. and C. Seeger, Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol 1994; 68(1): 6–13

    PubMed  CAS  Google Scholar 

  20. Kann, M. and W. Gerlich, Hepadnaviridae: structure and molecular virology. In Viral Hepatitis, A. Zuckerman and H. Thomas, Eds. 1998, Churchill Livingstone: London. pp. 77–105

    Google Scholar 

  21. Norder, H., et al., Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47(6): 289–309

    Article  PubMed  Google Scholar 

  22. Stuyver, L., et al., A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81(Pt 1): 67–74

    PubMed  CAS  Google Scholar 

  23. Shaw, T. and S. Locarnini, Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004; 2(6): 853–871

    Article  PubMed  CAS  Google Scholar 

  24. Stuyver, L.J., et al., Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33(3): 751–757

    Article  PubMed  CAS  Google Scholar 

  25. Domingo, E., Quasispecies and the development of new antiviral strategies. Prog Drug Res 2003; 60: 133–158

    PubMed  CAS  Google Scholar 

  26. Chin, R., et al., In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (−)-beta-d-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil. Antimicrob Agents Chemother 2001; 45(9): 2495–2501

    Article  PubMed  CAS  Google Scholar 

  27. Delaney, W.E.t., et al., Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45(6): 1705–1713

    Article  PubMed  CAS  Google Scholar 

  28. Ono-Nita, S.K., et al., Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother 2002; 46(8): 2602–2605

    Article  PubMed  CAS  Google Scholar 

  29. Sozzi, V., et al. Antiviral cross-resistance between clinically important HBV mutants: phenotypic testing using the recombinant HBV-Baculovirus assay system, global Antivir J HepDart 2005; 1 (Suppl 2)(Abstract 081): 79

    Google Scholar 

  30. Tenney, D.J., et al., Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48(9): 3498–3507

    Article  PubMed  CAS  Google Scholar 

  31. Brunelle, M.N., et al., Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 2005; 41(6): 1391–1398

    Article  PubMed  CAS  Google Scholar 

  32. Sheldon, J., et al., Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10(6): 727–734

    PubMed  CAS  Google Scholar 

  33. Delaney, W.E.t., et al., Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50(7): 2471–2477

    Article  PubMed  CAS  Google Scholar 

  34. Gunther, S., et al., Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52: 25–137

    Article  PubMed  CAS  Google Scholar 

  35. Yeh, C.T., et al., Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000; 31(6): 1318–1326

    Article  PubMed  CAS  Google Scholar 

  36. Ogata, N., et al., Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lami-vudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 1999; 59(3): 270–276

    Article  PubMed  CAS  Google Scholar 

  37. Delaney, W.E.t., et al., The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77(21): 11833–11841

    Article  PubMed  CAS  Google Scholar 

  38. Bartholomeusz, A., et al., Mechanistic basis for hepatitis B virus resistance to acyclic nucleoside phosphonate analogues, adefovir and tenofovir. Hepatology 2005; 42(Suppl 1): 594A

    Google Scholar 

  39. Lai, C.L., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36(6): 687–696

    Article  PubMed  CAS  Google Scholar 

  40. Leung, N.W., et al., Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33(6): 1527–1532

    Article  PubMed  CAS  Google Scholar 

  41. Locarnini, S., et al., Incidence and predictors of emergence of ade-fovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB). J Hepatol 2005; 42 (Suppl 2): A17

    Google Scholar 

  42. Perrillo, R.P., Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis 2005; 25(Suppl 1): 20–28

    Article  PubMed  CAS  Google Scholar 

  43. Colonno, R.J., et al., Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44(6): 1656–1665

    Article  PubMed  CAS  Google Scholar 

  44. Leung, N., Clinical experience with lamivudine. Semin Liver Dis 2002; 22(Suppl 1): 15–21

    Article  PubMed  CAS  Google Scholar 

  45. Delaney, W.E.t., S. Locarnini, and T. Shaw, Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 2001; 12(1): 1–35

    PubMed  CAS  Google Scholar 

  46. Zollner, B., et al., Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004; 39(1): 42–50

    Article  PubMed  Google Scholar 

  47. Bartholomeusz, A., B.G. Tehan, and D.K. Chalmers, Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther 2004; 9(2): 1419–60

    Google Scholar 

  48. Angus, P., et al., Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125(2): 292–297

    Article  PubMed  Google Scholar 

  49. Hadziyannis, S., Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hep Rev 1995; 1: 7–36

    Google Scholar 

  50. Bartholomeusz, A., et al., Molecular modelling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. Hepatology 2004; 40(Suppl 1): 246A

    Google Scholar 

  51. Schildgen, O., et al., Variant of hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 354(17): 1807–1812

    Article  PubMed  CAS  Google Scholar 

  52. Chang, T.T. and C.L. Lai, Hepatitis B virus with primary resistance to adefovir. N Engl J Med 2006; 355(3): 322–323; author reply 323

    Article  PubMed  CAS  Google Scholar 

  53. Yuen, L.K.W., A. Ayres, M. Littlejohn, D. Colledge, A. Edgely, W. J. Maskill, S.A. Locarnini, and A. Bartholomeusz. SEQHEPB: A sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 2007; 75: 64–74

    Article  PubMed  CAS  Google Scholar 

  54. Angus, P. and S. Locarnini, Lamivudine-resistant hepatitis B virus and ongoing lamivudine therapy: stop the merry-go-round, it's time to get off! Antivir Ther 2004; 9(2): 145–148

    PubMed  CAS  Google Scholar 

  55. Levine, S., et al., Efficacies of entecavir against lamivudine-resist-ant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46(8): 2525–2532

    Article  PubMed  CAS  Google Scholar 

  56. Warner, N., et al., Molecular modelling of entecavir resistant mutations in the hepatitis B virus polymerase selected during therapy. Hepatology 2004; 40 (Suppl 1)(4): 245A

    Google Scholar 

  57. Colonno, R.J., et al., Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. 57th Annual Meeting of American Association for the Study of Liver Disease. 2006; Abstract 110

    Google Scholar 

  58. Fung, S.K., et al., Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005; 43(6): 937–943

    Article  PubMed  CAS  Google Scholar 

  59. Mutimer, D., et al., Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000; 181(2): 713–716

    Article  PubMed  CAS  Google Scholar 

  60. Villet, S., et al., Sequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virus. Hepatology 2005; 42(Suppl 1)(4): 581A

    Google Scholar 

  61. Gonzales, M.J., et al., Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing. J Acquir Immune Defic Syndr 2003; 34(4): 398–402

    Article  PubMed  CAS  Google Scholar 

  62. Shafer, R.W., et al., Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 1998; 128(11): 906–911

    PubMed  CAS  Google Scholar 

  63. Natsuizaka, M., et al., Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymer-ase region. J Viral Hepat 2005; 12(2): 154–159

    Article  PubMed  CAS  Google Scholar 

  64. Ono, S.K., et al., The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest 2001; 107(4): 449–455

    Article  PubMed  CAS  Google Scholar 

  65. Yim, H.J., et al., Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44(3): 703–712

    Article  PubMed  CAS  Google Scholar 

  66. Shaw, T. and S. Locarnini, Combination chemotherapy for hepatitis B virus: the path forward? Drugs 2000; 60(3): 517–531

    Article  PubMed  CAS  Google Scholar 

  67. Lok, A., Natural history and control of perinatally acquired hepatitis B virus infection. Dig Dis 1992 1992; 10(1): 46–52

    Article  CAS  Google Scholar 

  68. Nowak, M.A., et al., Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93(9): 4398–4402

    Article  PubMed  CAS  Google Scholar 

  69. Locarnini, S., et al., Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9(5): 679–693

    PubMed  CAS  Google Scholar 

  70. Girones, R. and R.H. Miller, Mutation rate of the hepadnavirus genome. Virology 1989; 170(2): 595–597

    Article  PubMed  CAS  Google Scholar 

  71. Okamoto, H., et al., Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 1987; 57(4): 231–236

    PubMed  CAS  Google Scholar 

  72. Richman, D.D., The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000; 32(4 Pt 1): 866–867

    Article  PubMed  Google Scholar 

  73. Richman, D.D., The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res 1996; 29(1): 31–33

    Article  PubMed  CAS  Google Scholar 

  74. Zhang, Y.Y. and J. Summers, Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. J Virol 1999; 73(5): 3616–3622

    PubMed  CAS  Google Scholar 

  75. Zhang, Y.Y. and J. Summers, Low dynamic state of viral competition in a chronic avian hepadnavirus infection. J Virol 2000; 74(11): 5257–5265

    Article  PubMed  CAS  Google Scholar 

  76. Doo, E. and T.J. Liang, Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001; 120(4): 1000–1008

    Article  PubMed  CAS  Google Scholar 

  77. Seeger, C. and W.S. Mason, Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64(1): 51–68

    Article  PubMed  CAS  Google Scholar 

  78. Thibault, V., et al., Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16(1): 131–133

    Article  PubMed  Google Scholar 

  79. Niesters, H.G., et al., Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. J Med Microbiol 2002; 51(8): 695–699

    PubMed  CAS  Google Scholar 

  80. Lok, A.S., et al., Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 2002; 40(10): 3729–3734

    Article  PubMed  CAS  Google Scholar 

  81. Shaw, T., A. Bartholomeusz, and S. Locarnini, HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44(3): 593–606

    Article  PubMed  CAS  Google Scholar 

  82. Shaw, T. and S.A. Locarnini, Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J Viral Hepat 1999; 6(2): 89–106

    Article  PubMed  CAS  Google Scholar 

  83. Locarnini, S. and W.S. Mason, Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44(2): 422–431

    Article  PubMed  CAS  Google Scholar 

  84. Osborn, M.K. and A.S. Lok, Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 2006; 57(6): 1030–1034

    Article  PubMed  CAS  Google Scholar 

  85. Colgrove, R. and A. Japour, A combinatorial ledge: reverse tran-scriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance. Antiviral Res 1999; 41(1): 45–56

    Article  PubMed  CAS  Google Scholar 

  86. Shaw, T. and S.A. Locarnini, Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 1995; 15(4): 169–184

    PubMed  CAS  Google Scholar 

  87. Torresi, J., et al., Restoration of replication phenotype of lamivu-dine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 2002; 299(1): 88–99

    Article  PubMed  CAS  Google Scholar 

  88. Matthews, G.V., et al., Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20(6): 863–870

    Article  PubMed  CAS  Google Scholar 

  89. Delaney IV, W.E., et al., The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77(21): 11833–11841

    Article  PubMed  CAS  Google Scholar 

  90. Carman, W.F., The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4(Suppl 1): 11–20

    Article  PubMed  Google Scholar 

  91. Thibault, V., et al., Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16(1): 131–133

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Victorian Infectious Diseases Reference Laboratory, North Melbourne, VIC, Australia

    Stephen Locarnini

Authors
  1. Stephen Locarnini
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Executive Vice President & Chief Medical Offi cer, Idenix Pharmaceuticals, Cambridge, MA, USA

    Douglas L. Mayers MD

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Locarnini, S. (2009). The Hepatitis B Virus and Antiviral Drug Resistance: Causes, Patterns, and Mechanisms. In: Mayers, D.L. (eds) Antimicrobial Drug Resistance. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-59745-180-2_37

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-180-2_37

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-592-7

  • Online ISBN: 978-1-59745-180-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation